McDermott DF - Search Results

1

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY. Choueiri TK, et al. Among authors: mcdermott df. J Urol. 2011 Jan;185(1):60-6. doi: 10.1016/j.juro.2010.09.012. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074201

2

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Fallick ML, et al. Among authors: mcdermott df. J Urol. 1997 Nov;158(5):1691-5. doi: 10.1016/s0022-5347(01)64097-7. J Urol. 1997. PMID: 9334580 Clinical Trial.

3

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.

Atkins MB, Regan M, McDermott D. Atkins MB, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S. doi: 10.1158/1078-0432.CCR-040029. Clin Cancer Res. 2004. PMID: 15448028 Review.

4

Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.

McDermott DF, Atkins MB. McDermott DF, et al. Semin Oncol. 2006 Oct;33(5):583-7. doi: 10.1053/j.seminoncol.2006.06.004. Semin Oncol. 2006. PMID: 17045087 Review.

5

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.

Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Atkins MB, et al. Among authors: mcdermott df. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231. Clin Cancer Res. 2007. PMID: 17255291 Review.

6

Immunotherapy for metastatic renal cell carcinoma.

McDermott DF, Rini BI. McDermott DF, et al. BJU Int. 2007 May;99(5 Pt B):1282-8. doi: 10.1111/j.1464-410X.2007.06818.x. BJU Int. 2007. PMID: 17441925 Review. No abstract available.

7

What is standard initial systemic therapy in metastatic renal cell carcinoma?

Rini BI, McDermott D, Atkins M. Rini BI, et al. Clin Genitourin Cancer. 2007 Mar;5(4):256-63. doi: 10.3816/cgc.2007.n.001. Clin Genitourin Cancer. 2007. PMID: 17553205 Review.

8

Immunotherapy of metastatic renal cell carcinoma.

McDermott DF, Atkins MB. McDermott DF, et al. Cancer J. 2008 Sep-Oct;14(5):320-4. doi: 10.1097/PPO.0b013e31818675c4. Cancer J. 2008. PMID: 18836337 Review.

9

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group. Eisen T, et al. J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63. doi: 10.1093/jnci/djn319. Epub 2008 Oct 7. J Natl Cancer Inst. 2008. PMID: 18840822 Free PMC article. Clinical Trial.

10

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.

Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Cho DC, et al. Among authors: mcdermott df. J Immunother. 2009 Feb-Mar;32(2):181-5. doi: 10.1097/CJI.0b013e3181952b1d. J Immunother. 2009. PMID: 19238017

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters